IL157226A0 - Composition and method for potentiating drugs - Google Patents

Composition and method for potentiating drugs

Info

Publication number
IL157226A0
IL157226A0 IL15722601A IL15722601A IL157226A0 IL 157226 A0 IL157226 A0 IL 157226A0 IL 15722601 A IL15722601 A IL 15722601A IL 15722601 A IL15722601 A IL 15722601A IL 157226 A0 IL157226 A0 IL 157226A0
Authority
IL
Israel
Prior art keywords
composition
potentiating
drug
effective amount
cns
Prior art date
Application number
IL15722601A
Other languages
English (en)
Original Assignee
Gevys Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gevys Pharmaceuticals Ltd filed Critical Gevys Pharmaceuticals Ltd
Publication of IL157226A0 publication Critical patent/IL157226A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15722601A 2001-02-05 2001-12-19 Composition and method for potentiating drugs IL157226A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/775,794 US6833377B2 (en) 2001-02-05 2001-02-05 Composition and method for potentiating drugs
PCT/IB2001/002566 WO2002062388A1 (en) 2001-02-05 2001-12-19 Composition and method for potentiating drugs

Publications (1)

Publication Number Publication Date
IL157226A0 true IL157226A0 (en) 2004-02-19

Family

ID=25105521

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15722601A IL157226A0 (en) 2001-02-05 2001-12-19 Composition and method for potentiating drugs
IL157226A IL157226A (en) 2001-02-05 2003-08-04 Composition for potentiating drugs and its preparation

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL157226A IL157226A (en) 2001-02-05 2003-08-04 Composition for potentiating drugs and its preparation

Country Status (11)

Country Link
US (1) US6833377B2 (de)
EP (1) EP1359939B1 (de)
AT (1) ATE343399T1 (de)
AU (1) AU2002219417B2 (de)
CA (1) CA2437351A1 (de)
DE (1) DE60124144T2 (de)
DK (1) DK1359939T3 (de)
ES (1) ES2275624T3 (de)
IL (2) IL157226A0 (de)
PT (1) PT1359939E (de)
WO (1) WO2002062388A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192220A1 (en) * 2001-02-05 2005-09-01 Gevys Pharmaceuticas Ltd. Composition and method for potentiating drugs
US9877921B2 (en) 2005-09-09 2018-01-30 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US20070059361A1 (en) * 2005-09-09 2007-03-15 University Of Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
US20160045457A1 (en) 2005-09-09 2016-02-18 Ousama Rachid Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine
WO2007143676A2 (en) * 2006-06-05 2007-12-13 Verus Pharmaceuticals, Inc. Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
TW200816985A (en) * 2006-06-05 2008-04-16 Verus Pharmaceuticals Inc Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies
US20080108970A1 (en) * 2006-11-08 2008-05-08 Viertio-Oja Hanna E Control of Drug Administration
US8729070B2 (en) * 2008-02-20 2014-05-20 Targia Pharmaceuticals CNS pharmaceutical compositions and methods of use
CA2716080C (en) * 2008-02-20 2016-12-13 Targia Pharmaceuticals Cns pharmaceutical compositions and methods of use
US20120322884A1 (en) 2010-03-01 2012-12-20 University Of Manitoba Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US20140242177A1 (en) 2011-10-21 2014-08-28 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
CA3169368A1 (en) 2012-06-15 2014-01-09 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
PL2976072T3 (pl) 2013-03-22 2021-11-22 Nova Southeastern University Drobne cząstki epinefryny i sposoby ich stosowania do leczenia chorób reagujących na epinefrynę
WO2016027259A1 (en) * 2014-08-21 2016-02-25 Targia Pharmaceuticals Cns pharmaceutical compositions and methods of use
US20190343780A1 (en) * 2016-12-22 2019-11-14 Rvx Therapeutics Ltd. Low dose drug combinations for use in preventing and treating neuronal damage
US20220347122A1 (en) * 2019-03-15 2022-11-03 Ftf Pharma Private Limited Solutions for oral dosage

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947579A (en) 1974-06-03 1976-03-30 Nelson Research & Development Company Method and composition for potentiating neuroleptic drugs
DE3321969A1 (de) 1983-06-18 1984-12-20 Troponwerke GmbH & Co KG, 5000 Köln 2-pyrimidinyl-1-piperazin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4843071A (en) 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
US4788189A (en) 1988-02-29 1988-11-29 Glazer Howard I Method to treat smoking withdrawal symptoms by potentiated central noradrenergic blocking
US5431922A (en) 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
US5891842A (en) 1993-04-09 1999-04-06 Trustees Of Tufts College Methodology for eliciting an analgesic response in a living subject
CA2134038C (en) 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
EP0714663A3 (de) 1994-11-28 1997-01-15 Lilly Co Eli Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
AU706541B2 (en) 1995-06-09 1999-06-17 Euro-Celtique S.A. Formulations and methods for providing prolonged local anesthesia
US6511987B1 (en) 1999-11-12 2003-01-28 Neurogen Corporation Bicyclic and tricyclic heteroaromatic compounds

Also Published As

Publication number Publication date
PT1359939E (pt) 2007-02-28
US6833377B2 (en) 2004-12-21
EP1359939A1 (de) 2003-11-12
ES2275624T3 (es) 2007-06-16
DE60124144T2 (de) 2007-09-06
US20030004134A1 (en) 2003-01-02
DK1359939T3 (da) 2007-02-26
DE60124144D1 (de) 2006-12-07
WO2002062388A1 (en) 2002-08-15
CA2437351A1 (en) 2002-08-15
EP1359939B1 (de) 2006-10-25
ATE343399T1 (de) 2006-11-15
AU2002219417B2 (en) 2007-03-22
IL157226A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
IL157226A0 (en) Composition and method for potentiating drugs
MXPA02002249A (es) Composiciones farmaceuticas agradables al paladar para animales de compania.
HK1096034A1 (en) A solid dosage form comprising a fibrate
WO2002074247A3 (en) Pharmaceutical formulations for sustained release
HK1076605A1 (en) Formulations
MXPA03008756A (es) Derivados de n-(arilsulfonil) beta-aminoacidos que comprenden un grupo aminometilo substituido, el metodo de preparacion de los mismos y las composiciones farmaceuticas que los contienen.
WO2005032474A3 (en) Pharmaceutical compositions for prevention of overdose or abuse
WO2004043377A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
TW200510375A (en) New compounds
TNSN08140A1 (de)
NO962841D0 (no) Anvendelse av 2-hydroksy-5-fenylazobenzosyrederivater som colon cancer kjemopreventativer og kjemoterapeutiske midler
WO2005117895A3 (en) Compositions comprising meloxicam
WO2003045306A3 (en) Phenoxy amine compounds and compositions for delivering active agents
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
WO2010053861A3 (en) Biologically active amides
WO2001000617A3 (en) Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the same
WO2003035080A3 (en) A process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
WO2007011958A3 (en) Intraoral dosage forms of glucagon
PL377683A1 (pl) System terapeutyczny zawierający amoksycylinę i kwas klawulanowy
WO2004087880A8 (en) Compounds and their use to treat diabetes and related disorders
IL162860A0 (en) Sedative non-benzodiazepine formulations
EP1273301A3 (de) Pharmazeutische Zubereitungen, Wirkstoffe enthaltend, die sich für unerlaubte Verabreichung bieten
WO2002092565A3 (en) 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists
WO2004062564A3 (en) Sedative non-benzodiazepine formulations
MXPA05010707A (es) Combinaciones que comprenden farmacos anti-epilepticos para el tratamiento de desordenes neurologicos.